XML 27 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration Agreement - License Agreement - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Contract revenue - related party $ 6,573,000 $ 4,301,000 $ 24,988,000 $ 4,301,000  
Deferred revenue 1,172,000   1,172,000   4,379,000
Long-term deferred revenue 7,839,000   7,839,000    
Long term deferred Revenue, milestone payment received     5,000,000    
milestone payment will be recognized as revenue upon receiving the first regulatory approval 5,000,000   5,000,000    
License Agreement with Grifols [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Future reimbursable research and development expenses by partner     65,000,000    
Contract revenue - related party   4,300,000   4,300,000  
Payments for development milestones by partner     25,000,000    
Patent coverage or orphan drug designation period     10 years    
Percentage of reduction on royalty payment     50.00%    
Fully burdened development expenses 6,600,000 1,000,000 25,000,000 4,300,000  
Reimbursed amount of costs incurred       3,200,000  
License Agreement with Grifols [Member] | Prior Fiscal Year [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Reimbursed amount of costs incurred       $ 1,100,000  
License Agreement with Grifols [Member] | Minimum [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Royalty payments on net sales rate     12.50%    
License Agreement with Grifols [Member] | Maximum [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Royalty payments on net sales rate     20.00%